Nature Reviews Rheumatology ( IF 29.4 ) Pub Date : 2022-08-16 , DOI: 10.1038/s41584-022-00816-1 Lisa K Stamp 1 , Nicola Dalbeth 2
|
Gout management involves two broad aspects: treatment of gout flares to provide rapid symptomatic relief and long-term urate-lowering therapy to lower serum urate sufficiently to prevent gout flares from occurring. All of the major rheumatology societies recommend a target serum urate of <5 mg/dl (<0.30 mmol/l) or <6 mg/dl (<0.36 mmol/l), both of which are below the point of saturation for urate and therefore lead to monosodium urate crystal dissolution. In this Review, we describe the rationale for treat-to-target urate approach in the long-term management of gout and the current evidence and controversy around the appropriate serum urate targets.
中文翻译：
痛风治疗中血清尿酸盐目标的批判性评价
痛风管理涉及两个广泛方面：治疗痛风发作以提供快速症状缓解和长期降尿酸治疗以充分降低血清尿酸以防止痛风发作。所有主要的风湿病学会都推荐目标血清尿酸盐<5 mg/dl (<0.30 mmol/l) 或 <6 mg/dl (<0.36 mmol/l)，两者均低于尿酸盐的饱和点和因此导致尿酸单钠晶体溶解。在这篇综述中，我们描述了在痛风长期管理中采用目标尿酸盐治疗方法的基本原理，以及围绕适当血清尿酸盐目标的当前证据和争议。
京公网安备 11010802027423号